doi: 10.1016/j.jcjd.2019.09.003 110 HusainMBirkenfeldALDonsmarkMDunganKEliaschewitzFGFrancoDRet al
Additionally, a phase 2 trial of patients with type 2 diabetes has shown tirzepatide improves cardiovascular biomarkers [59, 60]
There is no drug without any side effects but the physician always weighs in the risk- benefit ratio before prescribing one as should be the case
esophagus cancer: n = 20, 0.02%, gastric cancer: n = 34, 0.03%
DAlessio et al
Short-acting GLP-1 RAs (e.g., exenatide, lixisenatide) were found to have a reduced impact on overnight and fasting blood glucose levels, while long-acting GLP-1 RAs (liraglutide, exenatide once weekly, dulaglutide, and semaglutide) were found to have an increased effect and better coverage on overnight and fasting blood glucose and HbA1c levels [18]